



EMVision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

ASX Release

LEADERSHIP TRANSITION

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”) announces today that, as part of its ongoing succession planning process, Scott Kirkland has been appointed Chief Executive Officer (CEO) and Managing Director from 1st July 2023. Mr Kirkland will succeed Dr Ron Weinberger, who has advised the Board of his intention to retire from his executive responsibilities, having served over five years in the role.

Ron will revert to a non-executive director position and will also act as a consultant to the EMVision management team for an initial term until July 2024 to play an important role supporting clinical and product development, commercial partnering and the regulatory approvals process.

Scott Kirkland co-founded EMVision in 2017 and has been an Executive Director of the Company since its establishment. He has played an instrumental role in the development and commercial application of EMVision’s revolutionary products, establishing the foundational team, leading corporate development, building clinical partnerships, including the Australian Stroke Alliance partnership, and securing awards of close to \$20M in Federal and State non-dilutive grants since inception. Prior to EMVision, Scott held several senior sales positions, including Head of Client Sales at Quantcast, a US-based venture backed technology company.

EMVision also announces that its current Head of New Product Development, Forough Khandan, will be appointed to the new role of Chief Technology Officer (CTO).

Ms Khandan joined EMVision as Head of Program Management in 2020 and has led the development and production of its 1st Generation portable brain scanner. She has over 15 years’ experience in medical device development having been Program Manager at Nanosonics (ASX:NAN) where she led a large multi-disciplined team of engineers and scientists. In that role, Ms Khandan was responsible for the development and delivery of Nanosonics’ second generation of trophon device from prototype through the regulatory approval process and after-market release.

EMVision’s Chairman, John Keep said: “Scott and Ron have worked side-by-side for the past several years and we are delighted to have someone of Scott’s calibre take over as CEO and Managing Director. Scott’s vision for EMVision and his vast experience gained over the past 6 years makes him the ideal candidate to lead EMVision through this next exciting phase of development as EMVision prepares for the successful commercialisation of the Company’s products. Both he and Forough have intricate knowledge of the business, product and clinical need and we have every confidence in the team’s ability to take EMVision through to commercial success globally. Ron has played a foundational role in building the Company and creating a diverse leadership team with a strong focus on product execution and generation of shareholder value. On behalf of the Board, I sincerely thank him for his dedicated service and commitment. We will continue to benefit from his valued input as a consultant and Board member and look forward to his ongoing involvement in the success of EMVision.”

EMVision CEO, Ron Weinberger said: “Building the company with the team over the last five years has been a privilege and now is a good time to hand over the leadership baton. EMVision has a well-defined strategy, a strong leadership team and is achieving positive momentum having recently commenced enrolment in the next phase of our multi-site clinical trials. Scott has been my right hand since the beginning and has been immersed in all aspects of the business operations and product development. I am confident

Scott, and the excellent team, will continue to build on our substantial opportunity. I look forward to continuing to support EMVision in delivering on its strategic priorities as a director, consultant and committed shareholder.”

Scott Kirkland, Executive Director said: “This transition will see a continuation of what Ron, the team and I have been building for a number of years. We have a great structure in place across the team and are at an exciting juncture in our journey towards improving the lives of millions of stroke victims. Personally, Ron has been a trusted advisor, friend and mentor and I’m grateful to be able to continue to access his insights and strategic advice. I’m looking forward to building on our strong foundation and continuing our momentum through our clinical trials and achieving our ambitions as a global leader in point-of-care medical imaging.”

APPENDIX 1: AMENDMENTS TO TERMS OF ENGAGEMENT OF DIRECTORS

As required by ASX Listing Rule 3.16.4, the Company provides the following changes to the material terms of Dr Ron Weinberger’s engagement as a Director of the Company:

- (i) the current Executive Services Agreement will be terminated effective 30 June 2023 with the remaining six month notice period waived;
- (ii) Non-Executive Director fees of \$45,000 plus statutory superannuation per annum from 1 July 2023; and
- (iii) a Service Fee of \$100,000 plus GST per annum under a Consultancy Agreement to provide strategic support to the executive management team for 1.5 days per week. The Consultancy Agreement commences on 1 July 2013 and has an Initial Term of 12 months which can be extended by mutual agreement. The Consultancy Agreement can be terminated with 4 weeks notice by either party.

The Company also notes that there are no changes to the material terms of Scott Kirkland’s engagement following his transition to Chief Executive Officer and Managing Director.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 800
andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neuroimaging devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision’s current expectations, estimates and projections about the industry in

which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.